The European Medicines Agency’s advisory group CHMP has adopted a positive opinion recommending approval of Accord Healthcare S.L.U.’s Zercepac (trastuzumab), a biosimilar to Roche’s (OTCQX:RHHBY) breast cancer med Herceptin.
CHMP has also given a thumbs up for Accord’s generic version of Bristol Myers Squibb’s (NYSE:BMY) blood thinner Eliquis (apixaban).
A final decision from the European Commission usually takes ~60 days.
https://seekingalpha.com/news/3578611-european-advisory-group-backs-herceptin-biosimilar-and-generic-eliquis
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.